Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & 3rd Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

 

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

 
 

Vision

Provide early detection, prognosis, and/or predicting response to available medications; develop new blood tests to better monitor treatment response; and, using blood-derived stem cells, test whether patients will be helped by emerging medication treatments.

Mission

Translate research into clinical care by defining patients who respond optimally to currently available and emerging therapies. Identify new therapeutic targets based on refined and granular understanding of disease mechanisms.

At-A-Glance: Dementia and Precision Medicine (Slideshow)

Map of Alzheimer's disease via regions. Title: People with dementia around the world. Americas: 9.4m in 2015, 15.8m in 2030, 29.9m in 2050. Africa: 4.0m in 2015, 7.0m in 2030, 15.8m in 2050. Europe: 10.5m in 2015, 13.4m in 2030, 18.6m in 2050. Asia: 22.9m in 2015, 38.5m in 2030, 67.2m in 2050. World: 46.8m in 2015, 74.7m in 2030, 131.5m in 2050.
Dementia is a big global health issueWorldwide, over 50 million people have dementia, and there are nearly 10 million new cases every year. 
collage of faculty portraits
Venturing into innovative leads

Researchers and clinicians at the Richman Center are collaborating to discover individualized therapeutics and diagnostics for earlier diagnosis and individualized interventions. 

Diagrams of exosomes. Extracellular vesicles include microvesicle and exosome (marked as circles). Secreted proteins are marked as triangles. Close-up diagram of exosome. Diagram of diseased cell as reference point for extracellular vesicles.
Exo-what? Exosomes could be the keyExosomes can even travel easily from the brain to the blood, they have the unique potential to tell us what’s going on in the brain from just a blood sample. This innovation has the potential for developing biomarkers for AD diagnosis and therapeutics.
diagram of clusters in big data analysis. smiley faces in various colors mixed into one column sorted into 4 clusters - each cluster is one color of the smiley faces (yellow, blue, green, red). Characteristics: Genetic (Polygenic risk - overall, Polygenic risk - system), Stem Cells (Neuronal function, Effect of treatments), Imaging (Structure, Function), Physiology (Inflammation, Brain perfusion, Exosomes), Clinical (Cognition, Behavior).
Leveraging big data

Collecting data from tens of thousands of patient medical records leverages the big data power analytics – for leads in subtyping for diagnostics and therapeutics.

Application of iPSCs in Precision Medicine. Medical record, patient's blood and clinical MRI are data gathered. Pluripotent stem cells source of specialized cells: cortical neurons, dopaminergic neurons, astrocytes, brain organoids, microglia. These specialized cells can serve as means of precision drug therapy.
Individualized brain stem cells

A unique personalized medicine approach involves the development of hiPSC models for the characterization of biologic subtypes of AD: from blood samples, brain cell lines can be individualized. 

At-A-Glance: Dementia and Precision Medicine (Slideshow)

Map of Alzheimer's disease via regions. Title: People with dementia around the world. Americas: 9.4m in 2015, 15.8m in 2030, 29.9m in 2050. Africa: 4.0m in 2015, 7.0m in 2030, 15.8m in 2050. Europe: 10.5m in 2015, 13.4m in 2030, 18.6m in 2050. Asia: 22.9m in 2015, 38.5m in 2030, 67.2m in 2050. World: 46.8m in 2015, 74.7m in 2030, 131.5m in 2050.
Dementia is a big global health issueWorldwide, over 50 million people have dementia, and there are nearly 10 million new cases every year. 
collage of faculty portraits
Venturing into innovative leads

Researchers and clinicians at the Richman Center are collaborating to discover individualized therapeutics and diagnostics for earlier diagnosis and individualized interventions. 

Diagrams of exosomes. Extracellular vesicles include microvesicle and exosome (marked as circles). Secreted proteins are marked as triangles. Close-up diagram of exosome. Diagram of diseased cell as reference point for extracellular vesicles.
Exo-what? Exosomes could be the keyExosomes can even travel easily from the brain to the blood, they have the unique potential to tell us what’s going on in the brain from just a blood sample. This innovation has the potential for developing biomarkers for AD diagnosis and therapeutics.
diagram of clusters in big data analysis. smiley faces in various colors mixed into one column sorted into 4 clusters - each cluster is one color of the smiley faces (yellow, blue, green, red). Characteristics: Genetic (Polygenic risk - overall, Polygenic risk - system), Stem Cells (Neuronal function, Effect of treatments), Imaging (Structure, Function), Physiology (Inflammation, Brain perfusion, Exosomes), Clinical (Cognition, Behavior).
Leveraging big data

Collecting data from tens of thousands of patient medical records leverages the big data power analytics – for leads in subtyping for diagnostics and therapeutics.

Application of iPSCs in Precision Medicine. Medical record, patient's blood and clinical MRI are data gathered. Pluripotent stem cells source of specialized cells: cortical neurons, dopaminergic neurons, astrocytes, brain organoids, microglia. These specialized cells can serve as means of precision drug therapy.
Individualized brain stem cells

A unique personalized medicine approach involves the development of hiPSC models for the characterization of biologic subtypes of AD: from blood samples, brain cell lines can be individualized. 

 

Alzheimer's and Dementia Research

Questions we're asking that inform us on how to best care for patients include:

geometric shapes icon

Big Data Power

stethoscope icon

Scaling Evidence-Based Care

test tube icons

Expedite Discovery - Closing the Loop

How can we fast track the research from clinic to test tube and back to the clinic with biomarkers for subtyping and for advancing therapeutics?

Innovation: Brain Scans

Innovation: New Blood Test

Can novel blood tests based on “exosomes” be used to learn about what’s going on in the brain so as to stage the AD brain disease and monitor treatment response?

Innovation: Stem Cell Models

Can blood derived stems cells be used to test whether individual patients will be helped by available and emerging medication treatments?

Clinical Trials

The Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease can facilitate access to several clinical trials conducted as part of the Johns Hopkins Memory and Alzheimer's Treatment Center (MATC) or the NIA-funded Johns Hopkins Alzheimer's Disease Research Center (ADRC).

 

Patient Care for Alzheimer's Disease 

The research we do directly impacts the treatment options available to our patients. Find out more about patient care for Alzheimer's Disease.

The Johns Hopkins Memory and Alzheimer's Treatment Center
The Johns Hopkins Bayview Medical Center
5300 Alpha Commons Drive, Floor 4
Baltimore, MD 21224

 
 

Faculty

Faculty Spotlight


Dimitrios Kapogiannis, M.D.

Dimitrios Kapogiannis, M.D. is Chief of the Human Neuroscience Unit at the National Institute of Aging and adjunct Associate Professor in the Department of Neurology at Johns Hopkins. He is a clinician-scientist, ABPN-certified in Neurology and UCNS-certified in Behavioral Neurology. His translational laboratory focuses on discovering novel biomarkers for preclinical diagnosis and therapeutic response in Alzheimer's and other neurodegenerative diseases. He has pioneered deriving Extracellular Vesicles enriched for neuronal and astrocytic origin from peripheral blood.

Meet Dr. Kapogiannis

 

Charitable Giving

Support diagnosis and treatment advancements and discoveries by Johns Hopkins scientists.

back to top button